Table 1.
Summary of Included studies.
| Country of Study | Topic (Type of Cancer and Status) | Study Design | Tools Used | Participant (%) Gender |
|
|---|---|---|---|---|---|
| The United States of America [21] | Breast Cancer (n = 57) | Survivors | Feasibility Study | Wearable Device and Questionnaire | 100% Women |
| Australia [22] | Breast Cancer (n = 80) | Survivors | RCT | Wearable Device + Text Messages and Personal Interviews + Mobile Application | 100% Women |
| The United States of America [23] | Breast Cancer (n = 34) | Survivors | RCT | Wearable Device and Questionnaire (Correlation) | 100% Women |
| Australia [24] | Breast Cancer (n = 80) | Survivors | RCT | Wearable Device and Questionnaire (Correlation) | 100% Women |
| The United States of America [25] | Breast Cancer (n = 20) | Survivors | RCT | Wearable Device + Group Sessions and Phone Calls | 100% Women |
| Canada [26] | Breast Cancer (n = 41) | Survivors | RCT | Wearable Device and Questionnaires (Correlation) | 100% Women |
| The Netherlands [27] | Breast Cancer (n = 8) | Survivors | Qualitative Study | Wearable Device and Questionnaires | 100% Women |
| United Kingdom [28] | Breast Cancer (n = 39) | Under Treatment | Non-RCT | Wearable Device, Questionnaire, and Behavioral Counseling Session | 100% Women |
| India [29] | Breast Cancer (n = 44) | Under Treatment | Non-RCT | Wearable Device + General group session + Questionnaire + Mobile Application | 95.4% Women |
| The United States of America [30] | Breast Cancer (n = 32) | Under Treatment | Pilot Study | Wearable Device + Mobile application + Text Messages | 100% Women |
| The United States of America [31] | Breast Cancer (n = 10) | Under Treatment | RCT | Wearable Device and Questionnaire | 100% Women |
| Germany [32] | Breast Cancer (n = 99) | Under Treatment | Feasibility Study | Wearable Device and Questionnaire | 100% Women |
| Central China [33] | Mixed Cancer (n = 112) | Under Treatment | RCT | Wearable Device | 76.2% Women |
| The United States of America [34] | Mixed Cancer (n = 38) | Under Treatment | Utility Study/Predictive Study | Wearable Device + Mobile application and Interview | 52% Women |
| The United States of America [35] | Mixed Cancer (n = 41) | Under Treatment | Observational Study | Wearable Device + Mobile application + Questionnaire | 56% Women |
| The United States of America [36] | Mixed Cancer (n = 33) | Under Treatment | Prospective cohort Study | Wearable Devices and Spirometer | 57.5% Women |
| Japan [37] | Mixed Cancer (n = 30) | Under Treatment | Feasibility Study | Wearable Device | 70% Men |
| France [38] | Mixed Cancer (n = 31) | Under Treatment | Pilot Study | Wearable Device + Mobile Application + Questionnaire | 55% Men |
| Ireland [39] | Mixed Cancer (n = 61) | Survivors | RCT | Wearable Devices + Goal-setting session + Telephone-delivered health-coaching sessions | 50% Men |
| The United States of America [40] | Mixed Cancer (n = 32) | Survivors | Feasibility Study | Wearable Device + Two group sessions + support phone call | 51% Men |
| Switzerland [41] | Mixed Cancer (n = 30) | Survivors | Feasibility Study | Fitbit + iPad (preloaded apps) + Questionnaires | 70% Men |
| The United States of America [42] | Mixed Cancer (n = 59) | Survivors | Pilot Study | Wearable Device and Questionnaire | 59.3% Women |
| The United States of America [43] | Mixed Cancer (n = 47) | Survivors | RCT | Wearable Device + Questionnaire + Social Media Intervention (Health Education) | 96% Women |
| Australia [44] | Colorectal and Endometrial cancer (n = 29) | Survivors | RCT | Mobile application (in-app chat service) + Wearable device + Questionnaires | 58% Women |
| Western Australia [45] | Colorectal Cancer (n = 61) | Survivors | RCT | Wearable Device + mHealth app + Peer-based virtual support group + Qualitative Interviews | 50% Women |
| The United States of America [46] | Colorectal Cancer (n = 39) | Survivors | RCT | Wearable Device and Questionnaire-based study | 58% Women |
| South Korea [47] | Colorectal Cancer (n = 75) | Under Treatment | Feasibility Study | Wearable device + Questionnaires + e-Patient Diary | 58.7% Men |
| The United States of America [48] | Colorectal Cancer (n = 40) | Under Treatment | Pilot Study | Wearable Device and Questionnaire-based study | 56.8% Women |
| Taiwan [49] | Lung Cancer (n = 12) | Under Treatment | Observational Study | Wearable Device and Questionnaire-based study | 58.33% Men |
| The United States of America [50] | Lung Cancer (n = 30) | Under Treatment | Observational Study | Wearable Device + Questionnaire + Educational handbook + Social support + Email-based coaching | 67% Men |
| The United States of America [51] | Lung Cancer (n = 18) | Under Treatment | Observational Study | Wearable Device and Questionnaire (Correlation) | 44% Women |
| South Korea [52] | Lung Cancer (n = 555) | Under Treatment | Usability Study | Wearable Devices + Questionnaire+ Educational handbook+ Social support + Email-based coaching | 61% Men |
| The United States of America [53] | Gastric cancer (n = 27) | Under Treatment | Cohort Study | Wearable Device + Mobile Application | 62.96% Men |
| Taiwan [54] | Gastric Cancer (n = 43) | Under Treatment | Group Study | Wearable Devices + Questionnaires | 51% Men |
| South Korea [55] | Liver Cancer (n = 31) | Under Treatment | Usability Study | Wearable Device + Daily text messages+ Questionnaire | 84% Men |
| The United States of America [56] | Blood Cancer (n = 11) | Under Treatment | Feasibility Study | Diary + Accelerometer | 66.6% Men |
| Japan [57] | Urothelial Carcinoma (n = 21) | Under Treatment | Cohort Study | Wearable Device | 84% Men |
| The United States of America [58] | Skin Cancer (n = 60) | Survivor | Observational Study | Wearable Devices + Questionnaire + Interviews | 60% Women |